ANKRD13A

Across TCGA pan-cancer cohorts, ANKRD13A Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ANKRD13A data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher ANKRD13A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ANKRD13A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRC, HNSC, and LIHC are the cancer types where ANKRD13A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	All	0.133	0.805	<.001	42	view →
HNSC	OS	Median	All	0.138	0.710	.001	24	view →
LIHC	OS	Median	All	0.290	0.707	.040	12	view →
BLCA	OS	Median	IV	0.153	0.599	.018	9	view →
UCEC	DFS	Median	All	0.955	0.628	.033	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
COAD	OS	Median	II,III,IV	0.702	0.851	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ANKRD13A–KIRC (OS)

Open the KIRC breakdown →